Caution in interpreting imaging‐based rankings in network meta‐analyses of metabolic dysfunction–associated steatotic liver disease therapies

Documenti analoghi

• Comparative efficacy and safety of pharmacologic therapies for metabolic dysfunction‐associated steatotic liver disease over 24 weeks in reducing liver steatosis and fibrosis: A network meta‐analysis
  di: Jiaxin Zhong, et al.
  Pubblicazione: (2025)
• An interpretable machine learning model for predicting metabolic dysfunction‐associated steatotic liver disease in patients with type 2 diabetes
  di: Zhuolin Zhou, et al.
  Pubblicazione: (2025)
• Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank
  di: Wenxiao Fan, et al.
  Pubblicazione: (2025)
• Non‐invasive diagnosis of metabolic dysfunction‐associated steatotic liver disease: Current status, challenges, and future directions
  di: Yuqing Ma, et al.
  Pubblicazione: (2025)
• Glycaemic control metrics and metabolic dysfunction–associated steatotic liver disease in children and adolescents with type 1 diabetes
  di: Claudio Maffeis, et al.
  Pubblicazione: (2024)